Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure

  • Moliner-Abós, Carles|||0000-0002-9264-5804
  • Mojón Álvarez, Diana
  • Rivas-Lasarte, Mercedes|||0000-0002-8704-3104
  • Belarte Tornero, Laia Carla|||0000-0003-2774-1290
  • Pamies Besora, Julia
  • Solé González, Eduard|||0000-0002-5727-9925
  • Fluvià, Paula|||0000-0002-4683-9122
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • López López, Laura|||0000-0002-8653-6206
  • Brossa Loidi, Vicens|||0000-0003-0403-6425
  • Pirla, Maria José
  • Mesado, Nuria
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Roig, Eulàlia|||0000-0002-3421-4985
  • Alvarez-Garcia, Jesus|||0000-0002-2015-6446
Sacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slower than expected. Our objective was to develop a score predicting the super-response to SV in HF outpatients. This is a retrospective analysis of 185 consecutive patients prescribed SV from two tertiary hospitals between September 2016 and February 2018. Super-responder was defined as a patient taking the drug and (i) without HF admissions, death, or heart transplant, and (ii) with a ≥50% reduction in NT-proBNP levels and/or an increase of ≥10 points in LVEF in a 12-month follow-up period after starting SV. Clinical, echocardiographic, ECG, and biochemical variables were used in a logistic regression analysis to construct a score for super-response to SV which was internally validated using bootstrap method. Out of 185 patients, 65 (35%) fulfilled the super-responder criteria. Predictors for super-response to SV were absence of both previous aldosterone antagonist and diuretic treatment, NYHA I-II class, female gender, previous 1-year HF admission, and sinus rhythm. An integrating score distinguished a low- (<25%), intermediate- (∼46%), and high-probability (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure

  • Rivas-Lasarte, Mercedes|||0000-0002-8704-3104
  • Maestro, Alba|||0000-0003-1785-3125
  • Fernández Martínez, Juan|||0000-0002-2011-2136
  • López López, Laura|||0000-0002-8653-6206
  • Solé González, Eduard|||0000-0002-5727-9925
  • Vives-Borrás, Miquel|||0000-0002-5345-4124
  • Montero, Santiago|||0000-0002-0984-3472
  • Mesado, Nuria
  • Pirla, Maria José
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Fluvià, Paula|||0000-0002-4683-9122
  • Brossa Loidi, Vicens|||0000-0003-0403-6425
  • Sionis, Alessandro|||0000-0003-0843-9512
  • Roig, Eulàlia|||0000-0002-3421-4985
  • Cinca, Juan|||0000-0003-4819-4265
  • Alvarez-Garcia, Jesus|||0000-0002-2015-6446
Residual pulmonary congestion at hospital discharge can worsen the outcomes in patients with heart failure (HF) and can be detected by lung ultrasound (LUS). The aim of this study was to analyse the prevalence of subclinical pulmonary congestion at discharge and its impact on prognosis in patients admitted for acute HF. This is a post-hoc analysis of the LUS-HF trial. LUS was performed by the investigators in eight chest zones with a pocket device. Physical exam was subsequently performed by the treating physicians. Primary outcome was a combined endpoint of rehospitalization, unexpected visit for HF worsening or death at 6- month follow-up. Subclinical pulmonary congestion at discharge was defined as the presence of ≥5 B-lines in LUS in absence of rales in the auscultation employing the area under the ROC curve. At discharge, 100 patients (81%) did not show clinical signs of pulmonary congestion. Of these, 41 had ≥5 B-lines. Independent factors related with the presence of subclinical pulmonary congestion were anaemia, higher New York Heart Association (NYHA) class, and N terminal pro brain natriuretic peptide (NT-proBNP). After adjusting by propensity score analysis including age, renal insufficiency, atrial fibrillation, NYHA class, NT-proBNP levels, clinical congestion, and the trial intervention, the presence of subclinical pulmonary congestion at discharge was a risk factor for the occurrence of the primary outcome (hazard ratio 2.63; 95% confidence interval: 1.08-6.41; P = 0.033). Up to 40% of patients considered 'dry' according to pulmonary auscultation presents subclinical congestion at hospital discharge that can be detected by LUS and implies a worse prognosis at 6- month follow-up. Comorbidities, high values of natriuretic peptides, and higher NYHA class are the factors related with its presence.